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Abstract: Gliomas are a group of heterogeneous primary central nervous system (CNS) tumors 
arising from the glial cells. Malignant gliomas account for a majority of malignant primary CNS 
tumors and are associated with high morbidity and mortality. Glioblastoma is the most frequent 
and malignant glioma, and despite the recent advances in diagnosis and new treatment options, 
its prognosis remains dismal. New opportunities for the development of effective therapies for 
malignant gliomas are urgently needed. Magnetic hyperthermia (MHT), which consists of heat 
generation in the region of the tumor through the application of magnetic nanoparticles subjected 
to an alternating magnetic field (AMF), has shown positive results in both preclinical and clinical 
assays. The aim of this review is to assess the relevance of hyperthermia induced by magnetic 
nanoparticles in the treatment of gliomas and to note the possible variations of the technique 
and its implication on the effectiveness of the treatment. We performed an electronic search in 
the literature from January 1990 to October 2010, in various databases, and after application of 
the inclusion criteria we obtained a total of 15 articles. In vitro studies and studies using animal 
models showed that MHT was effective in the promotion of tumor cell death and reduction of 
tumor mass or increase in survival. Two clinical studies showed that MHT could be applied 
safely and with few side effects. Some studies suggested that mechanisms of cell death, such 
as apoptosis, necrosis, and antitumor immune response were triggered by MHT. Based on these 
data, we could conclude that MHT proved to be efficient in most of the experiments, and that 
the improvement of the nanocomposites as well as the AMF equipment might contribute toward 
establishing MHT as a promising tool in the treatment of malignant gliomas.
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Introduction
In recent decades, a major challenge for oncologists and neuroscientists has been 
the understanding of biological mechanisms underlying the formation of tumors in 
the central nervous system (CNS), as well as the development of therapies that can 
stabilize, reduce or even eliminate these tumors. Primary malignant CNS tumors 
represent 1.49% of all cancers; however, although relatively rare, they are associated 
with high morbidity and mortality.1 Most of these tumors that originate from glial cells 
are usually referred to as gliomas.2
Gliomas are a group of heterogeneous CNS neoplasms that can be classified 
according to the glial cell of origin (ie, astrocytes, oligodendrocytes, ependymal cells, 
or choroid plexus cells).3 Gliomas are neuroepithelial tumors, which account for 
33% of primary tumors and 79% of malignant CNS tumors. Astrocytomas represent 
75% of all gliomas, and glioblastomas form 51.7% of cases.1 Glioblastoma is the most International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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frequent and malignant astrocytoma, and despite advances 
in diagnosis and treatment of these tumors, their prognosis 
remains dismal.4,5 The development of new effective thera-
pies is urgently needed. Hyperthermia induced by magnetic 
nanoparticles in tumor tissues is a potential therapeutic tool 
and has been evaluated by various ex-vivo experiments 
(fragments of tumor tissue removed by surgery) in animal 
models, with promising results, prompting Phase I studies 
in humans.6,7
Hyperthermia is a therapeutic procedure that promotes 
the increase of temperature in body tissues in order to change 
the functionality of the cellular structures. Its activity is based 
on the fact that a temperature increase of between 41°C and 
42°C can induce tumor cell death, as the tumor cells are less 
resistant to sudden increases in temperature than the normal 
surrounding cells.8 The rise in temperature changes the 
functioning of many enzymatic and structural proteins in the 
cells, in turn altering cell growth and differentiation, which 
can induce apoptosis.9,10 Changes triggered by hyperthermia 
in the cell membrane lead to a reduction in transmembrane 
transport and destabilize its potential.11,12 It is also known that 
the rise in temperature can affect the synthesis of nucleic acids 
and inhibition of repair enzymes, and promote changes in the 
conformation of DNA.13 The temperature increase required 
by hyperthermia can be achieved via different heat sources, 
such as electromagnetic radiation waves (hyperthermia by 
radiofrequency or microwave),14,15 ultrasound waves,16–18 or 
electrically induced hyperthermia.19 These techniques have 
shown good results, however, the major problem with pres-
ent conventional methods is reaching a heat homogenous 
distribution and therapeutic temperatures in the deep region 
of the tumor to be treated. In this sense, treatment failure 
results from an insufficient temperature rise in some parts 
of the tumor, allowing the tumor to recur. What also must be 
avoided is the excessive increase in temperature which would 
cause peritumoral tissue damage. The magnetic hyperthermia 
(MHT) technique has partly solved these problems.
Studies on the application of magnetic materials to 
promote hyperthermia began with Gilchrist et al20 in the late 
1950s. After this work, many empirical studies have been 
carried out to evaluate the therapeutic expression in   different 
tumor types. However, the results of these preliminary studies 
had their widespread use in academic circles only in the 
early 1990s, and today there are a small number of clinical 
studies in this area.21–24 Thus, more detailed studies on the 
physical limitations, degree of toxicity, and efficiency that 
would allow a better applicability of the method to humans 
are needed.
The principle of MHT comprises the administration of a 
magnetic fluid within the tumor for subsequent application 
of an alternating magnetic field (AMF), which will promote 
warming of the region.20 At present, MHT is presented as a 
noninvasive promising technique, efficient in implementing 
hyperthermia in deep and inaccessible tissues. The advan-
tage of MHT is related to its specificity to tumorigenic 
tissues, ensuring less damage to healthy tissues due to the 
uniform distribution of temperature and the high rate of 
heat transfer.
The efficiency of the MHT technique is extremely 
dependent on the different properties of the particles, such as 
size, magnetization, and the value of the Curie temperature. 
The Curie temperature is the maximum   temperature 
reached by a magnetic particle. Knowledge about the Curie 
  temperature of a magnetic particle allows an efficient 
temperature control to avoid overheating the tissue.25 Of 
great importance are also the different parameters of the 
magnetic field used, such as intensity and frequency that 
will achieve the desired temperature.26 The main aim in this 
area is to improve the parameters above in order to obtain 
the best treatment efficacy. At present, some preliminary 
studies23,27 that practice the clinical use of MHT to treat 
gliomas suggest that the superparamagnetic nanoparticles 
of iron oxide (SPION) have appropriate intratumoral dis-
tribution and are able to promote controlled heating of the 
region to hyperthermic temperatures without causing major 
side effects. In this sense, the objective of this review is to 
find in the literature, studies that discuss the relevance of 
hyperthermia induced by magnetic nanoparticles subjected 
to an AMF, in the treatment of gliomas. We have included 
preclinical testing (application of MHT in tumor models) 
and even clinical studies, which have been used with this 
technique, as therapy alone or even associated with other 
therapies. Although gliomas are exclusively CNS tumors, 
we have included animal model studies even where tumors 
have been implanted outside the CNS, as they originated 
from glioma cell lines (eg, T-9 rat glioma cells).
Methods
The search for publications was conducted from January 
1990 to October 2010 based on the electronic data banks: 
ISI Web of Science and PubMed. The search keywords were 
as follows: [(Brain tumor), (glioma) or (glioblastoma)] and 
[(magnetic fluid hyperthermia), (magnetic hyperthermia) 
or (induction heating)]. In this review, three authors (LM, 
JBM, and TRO) independently checked the titles and 
abstracts of the articles obtained in the electronic search. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Next, three other authors (LFG, LFP, and TTS) verified 
the quality of the   methods, inclusion criteria, and data to be 
  collected.   Following this, three more authors (ACS, SMFM, 
and EAJr) extracted the data and tabulated the results.
The publications had to satisfy the following inclu-
sion criteria: 1) published in English, 2) original works, 
3)   hyperthermia was used for the purpose of promoting glioma 
tumor cell death, and 4) used nanoparticles of iron oxide under 
the influence of an AMF as a mediator of hyperthermia.
Results
We identified 71 publications by electronic search. 
  Considering the inclusion criteria, we selected 15 articles: 
3 in vitro studies,28–30 10 animal model studies,23,29,31–37 and 
2 clinical studies.6,27 Although there are different centers 
around the world that study magnetic hyperthermia as 
a cancer therapy, studies of application in glioblastoma 
tumors are concentrated mainly in two research centers, 
the   Department of Biotechnology, School of Engineering, 
Nagoya   University, Japan and the Department of Radiation 
Medicine, University of Chariteé Medicine, Germany.
Physical parameters for efficient heating
Physicochemical properties of magnetic 
nanoparticles
The studies in vitro, in vivo, and in humans, in this review, used 
SPION corresponding to the crystalline phase of   magnetite, 
whose physicochemical characteristics are summarized in 
Table 1. In the in vitro studies,28–30 the diameter of the nucleus 
of the SPION ranged from 20 to 35 nm. In vivo   applications 
used SPION in the range of 1–35 nm, while human studies 
were performed with a SPION from 12 to 15 nm.   Colloidal 
suspensions with   various concentrations of iron, ranging 
from 0.2 to 1 × 107 mg/mL (Table 1), were employed in these 
studies. In all studies of this review, the hydrodynamic diam-
eter of SPION was not notified, but the aminosilane   particles 
produced by MagForce   Nanotechnologies AG (Berlin, 
  Germany) had a   hydrodynamic diameter of ∼20 nm.38
For in vitro applications, the coating material of SPION 
was a lipid layer (N-(α-trimethylammonioacetyl)-didodecyl-
D-glutamate chloride [TMAG],   dilauroylphosphatidylcholine 
[DLPC], dioleoylphosphatidyl-ethanolamine [DOPE], 
1:2:2 cationic; DLPC, DOPE, 1:1 neutral)28,29 and PVP 
(  polyvinylpyrrolidone) with poly (ethylene glycol) (200) methyl 
ether methacrylate (PEG200MMA), PEG1000MMA, trieth-
ylene glycol dimethacrylate (TEGDMA), and poly (  ethylene 
glycol) (400)   dymethacrylate (PEG400DMA).30 For in vivo 
applications, the lipid layers29,31–34,36   carboxymethylcellulose 
(CMC)37 and carboxydextran DDM128P6 aminosilane23 
were used, and for human studies SPION coated with 
aminosilane6,27 was used.
Most studies used magnetite coated with cationic 
liposomes (MCL) and SPION coated with aminosilane. For in 
vitro and in vivo studies that used MCL,28,29,31–34,36 the affinity 
of MCL to the cells, compared with the liposomes of neutral 
charge, was enhanced due to the electrostatic interaction 
on the basis of the positive charge of the MCL; a higher 
affinity was produced by electrostatic interaction with the 
phospholipid cell membrane that was negatively charged. In 
the in vivo studies performed with MCL for the treatment of 
tumors,32,33 the tumor regression was associated with the high 
distribution of MCL, presenting a great potential for treatment 
due to necrosis of the tumorigenic cells, not only by heating, 
but also by inducing an immune response.34 Le et al35 have 
demonstrated that the MCL, besides being used for tumor 
hyperthermia, could also be linked to an antibody fragment, 
which would increase its specificity for glioma cells in vitro 
and in vivo. Human studies done with SPION coated with 
aminosilane6,27 showed that the SPION presented themselves 
as good specific markers in the therapy of tumors. The distri-
bution of SPION was analyzed by autopsies on brains, which 
showed that the SPION installed were dispersed and distrib-
uted in aggregate forms in the region of the necrosis, and the 
distribution was restricted to the sites of instillation.27
Alternating current (AC) magnetic field system  
to MHT therapy
From Table 1 it can be observed that the oscillation frequency 
of the magnetic field, collected for all studies, is mainly 
defined as being close to 100 kHz (ranging from 88.9 to 
150 kHz); there is only one article that uses a frequency 
of 297 kHz.30 The intensities of the magnetic field used to 
promote heating throughout the protocol are not commonly 
presented in the articles, but the maximum capacity of the 
magnetic field generators is between the values of 11.0 and 
30.6 kA/m. With respect to magnetic field applicator configu-
ration, the horizontal coil and ferromagnetic core coil have 
been used as major setup to in vivo experiments; however, for 
clinical trials, the unique magnetic field applicator available 
has a ferrite-core configuration. In two in vitro studies,28,30 
they used the configuration of the applicator in vertical 
coil, and in only one study29 the configuration was with a 
horizontal coil. In most studies, the specific loss of power or 
specific absorption rate are not indicated; however, studies 
performed by Shinkai et al,28 Le et al,35 and Rabias et al39 
reported values of 140, 96, and 286 W/g, respectively.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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effectiveness of MHT therapy
Of the 15 publications that we have selected for this review, 
9 evaluated the MHT technique used in animal models of 
rats and mice; 2 performed experiments in cell culture, and 
1 study used both animal and cell cultures. Three stud-
ies involved humans. The description of the results was 
subdivided as follows: in vitro experiments that included tests 
in cell   culture; in vivo experiments in which animal models 
were used; ex-vivo and in vivo experiments in humans.
In vitro experiments
In 1996, Shinkai et al28 verified the efficiency of MCL as a 
generator of intracellular hyperthermia. With the application 
of an AMF in glioma cells (T-9), in the presence of MCL 
(concentration 7.2 mg/mL), the temperature of the ‘pellet’ 
center reached 42.6°C in 20 minutes. Cell viability decreased 
when AMF was applied, reaching 0 number of cells after 
40 minutes. Moreover, MCL was seen to be absorbed very 
well by the cells, reaching 80% of the maximum absorption 
in 1 hour, thereby facilitating the heating of the cells.
Posteriorly, Ito et al,29 in an in vitro study, observed 
that hyperthermia, in addition to lysing the cells, promoted 
an antitumor immune response by activation of heat shock 
proteins (HSP70). After application of AMF, the temperature 
reached 42°C for 30 minutes by using MCL at a   concentration 
of 100 µg/mL. Hyperthermia promoted necrosis in three 
types of T-9 cell lines developed. They observed the release 
of HSP70 protein mainly in the type T-9/HSP70.
In another more recent study using glioblastoma cells 
(M059K), Meenach et al30 evaluated the ability of a hydrogel 
(based on polyethylene glycol) with nanoparticles, in a 
concentration of 7.93 mg/mL, to promote hyperthermia. 
There was cell death by thermal ablation (63°C) where 
hydrogel with the nanoparticles was applied, effective in the 
region of the plate, but there was no death in the surround-
ing region. Table 2 summarizes the main findings of the in 
vitro experiments.
In vivo experiments – animal model
Therapeutic protocol in animal models
Table 3 compares animal models and shows that the selected 
studies evaluate the effects of MHT therapy on tumor sizes 
between 3 and 18 mm, with the highest frequency between 
10 and 18 mm, which has been included in 6 of 10 articles. 
One study37 did not report the size of the tumor evaluated.
The cell lines used in most studies (6 of 10 studies) were 
T-9 cells implanted into Fischer F344 rats.23,29,31–34,37 The 
minimum number of cells inoculated ranged from 1 × 105 to 
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3 × 107 cells. Only in 2 studies, the cells were implanted in the 
brain regions,23,37 and in the remaining studies, the cells were 
applied subcutaneously. For the interval of tumor dimension 
studied, the amount of iron introduced into the tumor was 
between 3 µg and 3 mg, as per the comparison of treatment 
protocols presented in Table 4 and taking into consideration 
the nine articles that provided such information. With regard 
to the heating time, Table 4 shows that the authors used 
protocols of up to 60 minutes. However, in most studies, the 
duration was 30 minutes. In this sample, 7 articles favored 
an increase in the number of applications of AMF, with an 
increase in the exposure time of each application; two being 
the maximum number of applications observed (Table 4). 
The therapeutic temperature of choice was found to be 
between 43°C and 47°C, but most often it was found to 
be at   temperatures of 44°C32,34,37 and 45°C.29,31,33 In most 
studies (8 of 10 studies) MHT was tested alone; however, 
2 studies29,36 found that gene therapy added to MHT would 
promote a greater reduction in tumors.
effectiveness of MHT in animal models
The effectiveness of MHT in models of gliomas was first 
reported by Yanase et al.31 In this study, Fisher F344 rats 
were used. T-9 cell cultures pre-incubated with MCL were 
injected subcutaneously. After 20 minutes of AMF, the 
temperature reached 43°C and went up to 45°C. However, 
rectal temperature was maintained between 35°C and 36.5°C. 
The application of AMF, thrice, for 60 minutes, at intervals 
of 12 hours, was able to completely inhibit tumor cell growth 
in rats, which were observed for up to 90 days.
In another publication, Yanase et al32 obtained similar 
results; however, the MCL was injected in Fisher rats with 
previously developed tumors. After 15 minutes of AMF, 
the maximum tumor temperature reached 44°C, with little 
change in rectal temperature (35°C and 37°C). The group 
that received three applications of magnetic irradiation for 
30 minutes at intervals of 24 hours had a tumor reduction 
of 87.5%. Histological analysis revealed that in the control 
group that received no AMF, the MCL was restricted to the 
area of administration. However, the groups that received 
AMF showed a homogeneous distribution of MCL that also 
coincided with the necrotic regions.
In the same year, Yanase et al33 investigated a possible anti-
tumor immune response induced by hyperthermia in the same 
tumor model as described earlier in mice (T-9);   however, tumor 
induction was performed on both sides of the animal. The 
heat induction was effective and reached 43°C in the tumor 
region after a 10 minute application of AMF. The group that 
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received three sessions of 30 minutes of magnetic irradiation, 
with intervals of 24 hours, had a complete   regression of the 
tumor on the left side. Although the right side did not receive 
an application of MCL, it also had total regression of the tumor. 
Histological analysis revealed the presence of immunocytes 
(CD3, CD4, CD8, and natural killer [NK] cells) in the group 
exposed to hyperthermia in the tumor tissues on both sides 
(left and right). After magnetic irradiation, the cured rats were 
injected again with T-9 cells and also with cell lines of malig-
nant fibrous histiocytoma (MFH). The authors observed the 
development of MFH cells only, showing a specific immune 
response of the tissue to T-9 cells.
The same antitumor immune response triggered by 
hyperthermia, proposed by Yanase,32 was confirmed by 
Shinkai et al.34 Soon after tumor growth (T-9 cells) in Fisher 
rats, after a 15-minute application of AMF, it was observed 
that the maximum temperature in the tumor reached 44°C. 
The maximum duration of application of AMF was 
30 minutes, and in this time interval, animals in the group 
receiving magnetic irradiation had a complete regression 
of the tumor after repeated sessions. After regression, no 
recurrence was observed for a 3-month period. Injected 
MCL of 80% to 90% accumulated in the tumor tissue. It was 
suggested that regression and no recurrence of tumor was on 
account of an immune response (activation of CD4, CD8, 
and NK cells) activated by hyperthermia.
In 2001, Ito et al36 suggested that hyperthermia   combined 
with gene therapy could be an effective therapy for the 
treatment of tumors. For the development of the tumors, 
human glioma cells (U251-SP) were implanted in the flanks 
of mice. The application of AMF in the tumor, in the   presence 
of MCL, was able to produce heating to 46°C after 3   minutes. 
The concomitant injection in the tumor of   pGadFNT, 
a   promoter of the tumor necrosis factor (TNF) that was 
activated by hyperthermia and MCL, promoted an increase 
of gene expression, TNF-α, after the application of AMF. 
  Application of pGadFNT and MCL and subsequent 
  application of AMF dramatically reduced the tumor, and 
it was the largest decrease compared with groups in which 
these compounds were administered alone.
Also in 2001, Le et al35 demonstrated that the effectiveness 
of MCL in the destruction of tumors could be increased when 
Table 3 Comparison of animal models used to evaluate glioma by MHT therapy
Study Tumor  
cell line
Animal Gender Age  
(weeks)
Injection  
site
Minimum 
inoculation 
(cells)
Days to start 
MHT after 
tumor cell 
inoculation
Tumor 
size (mm)/ 
shape
Yanase  
et al31
T-9 Fisher  
rat F-344
Female 7–8 Subcutaneous 
(left femoral 
region)
1 × 106 – 3/ellipsoidal
Yanase  
et al32
T-9 Fisher  
rat F-344
Female 6–7 Subcutaneous 
(left femoral 
region)
1 × 107 11 13–18/ 
ellipsoidal
Yanase  
et al33
T-9 Fisher  
rat F-344
Female 6–7 Subcutaneous 
(left and right 
femoral region)
1 × 107 11 13–18/
ellipsoidal
Shinkai  
et al34
T-9 Fisher  
rat F-344
Female 6–7 Subcutaneous 
(left femoral 
region)
1 × 107 11 13–18/ 
ellipsoidal
Ito et al36 U-251-SP Athymic  
nude mice
Female 4 Right flank 3 × 107 – 8/−
Le et al35 U-251-SP KSN-nu/nu  
nude mice
Female 4 Subcutaneous 
(femoral region)
– 21 10/
ellipsoidal
Ohno  
et al37
T-9 Fisher  
rat F-344
Female 4 Right cerebral 
hemisphere
5 × 106 8 –
Ito et al29 T-9 Fisher  
rat F-344
Female 6 Subcutaneous 
space
1 × 107 – 10/−
Jordan  
et al23
RG-2 Fisher  
rat F-344
Male – Thalamus  
region
1 × 105 4 3–4/round
Rabias  
et al39
C6 wistar rat Male – Subcutaneous 
(anterior 
bregma region)
8 × 106 28 5–10/−
Abbreviation: MHT, magnetic hyperthermia.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Magnetic hyperthermia for treatment of gliomas
it was coupled with a fragment of a specific antibody for 
tumors (Fab fragment). Thus, tumors were developed in 
mice with human glioma cells (U251-SP). It was found that 
the MCL conjugated to the antibody Fab was captured by 
tumor cells seven times more than MCL without a specific 
antibody, and after application of AMF, there was a rapid 
increase in tumor temperature reaching 40°C in 5 minutes 
and 43°C after 30 minutes. Moreover, tumor growth was 
inhibited for up to 2 weeks.
In 2002, Ohno et al37 tested the efficacy of a new SPION, 
CMC ‘stick type’, based on a magnetite, in the generation 
of heat. This SPION was evaluated in tumors developed in 
Fisher rat brains that were inoculated with T-9 cells. The nano-
particles were effectively heating the tumor tissue to 44.4°C, 
after AMF application, besides being widely   distributed after 
three applications. It was found that the nanoparticles did not 
invade normal brain tissues surrounding the tumor. Total 
remission of the tumor was observed in only one animal in the 
group, which underwent three sessions of MHT. Moreover, 
this group verified higher survival when compared with other 
groups. Thus, the data showed a good performance by the 
nanoparticles in the induction of hyperthermia.
In the studies of Ito et al, hyperthermia was still identified 
as an inducer of antitumor immune factors.29 In this study, it 
was hypothesized that hyperthermia activated HSPs, which 
in turn triggered an antitumor immune response. Tumors in 
Fisher rats developed from the inoculation of T-9 cells into the 
subcutaneous space. The application of AMF in the tumor, in 
the presence of MCL, was able to produce heating up to 42°C 
after 4 minutes, reaching 45°C. Along with the heating there 
was an increase in HSP70 protein expression. It was observed 
that the HSP70 protein was able to trigger an antitumor 
immune response. Moreover, it was found that on account of 
hyperthermia the dead cells released HSP70 protein.
Recently, Jordan et al23 observed the efficiency of 
hyperthermia promoted by SPION with two different types 
of coatings (carboxidextran and aminosilane) in an animal 
model of brain tumor (RG-2). In relation to the controls, 
after MHT, the tumors did not differ in dimension or 
histopathology. There was a decrease in the level of cell 
proliferation in the group that used nanoparticles coated 
with aminosilane. In the same group there was an increase 
in the average survival of animals. The gain in survival was 
correlated with increased intratumoral temperature, observed 
during the treatment. Nanoparticles coated with aminosilane 
remained stable within the tumor when compared with those 
coated with carboxidextran, and were well distributed in the 
tumor tissue after histological analysis. It was concluded 
that thermotherapy using SPION coated with aminosilane 
was effective in causing an extension of survival in animals 
submitted to the tumor model.
Finally, Rabias et al39 demonstrated in a study of 
  synthesis and characterization, the efficiency of a maghemite 
ferrofluid coated with dextran with high surface charge 
(  denominated S3). The results showed that even with the 
injection of small quantities, there was a rapid heating and 
good distribution in tumor. An amount of 150 uL of ferrofluid 
was injected into extracranial tumors developed from the 
C6 cell line in Wistar rats.
During the application of AMF of low intensity (11 kA/ma 
150 kHz for 20 minutes), performed by   monitoring the 
  temperature with infrared image, they observed that the 
  heating was restricted to the tumor area. After treatment, 
  animals were submitted to histological analysis, and there was 
extensive damage or even the dissolution of the tumor   tissue. 
This damage was restricted to the tumor area. In   control 
groups where the ferrofluid was injected without application 
of a magnetic field or even in the group that there was no 
injection, but the animals were   submitted to AMF, there was 
no detected tumor damage. Thus, they concluded that the 
ferrofluid tested, due to its high surface charge, prevented the 
formation of clusters, with a good   dispersion in tumor tissue 
during heating, showing its   excellent   applicability in living 
organisms.
The main findings observed in the studies using 
  animal models for evaluation of MHT to treat gliomas are 
  summarized in Table 3.
In vivo and ex-vivo experiments in humans
Clinical studies were started by Maier-Hauff et al,6 wherein 
the efficacy and tolerability of hyperthermia induced by 
SPION-coated aminosilane combined with radiotherapy 
was evaluated in 14 patients for the treatment of recurrent 
glioblastoma multiforme. The eligibility criteria for the study 
were: age greater than or equal to 18 years, life expectancy 
greater than 3 months, tumor diameter less than 5 cm, no 
multilocular growth, and no metal material near the tumor 
focus. Each patient received an average of six sessions of 
thermotherapy. These sessions were preceded with instilla-
tion of approximately 0.2 mL of magnetic fluid per mL 
tumor volume. The average intratumoral temperature reached 
during the sessions was 44.6°C.
After each thermotherapy session, the patients underwent 
a simple fraction (2 Gy) of radiotherapy series of 30 Gy, on 
average. All the patients were tolerant of the instillation of 
SPION, not showing any complications or adverse effects. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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The implementation of AMF brought few side effects, 
except in some patients who complained of a mild heating 
sensation in the head. Aspects for survival and local tumor 
growth were analyzed. Nine patients had their deaths related 
to tumor progression; however, four deaths were not related 
to tumor growth or thermotherapy, but were a result of 
prescription medication. It was concluded that MHT could 
be satisfactorily used in treating brain tumors because they 
could be safely applied in patients with glioblastoma, with 
minimal or no local symptoms.
In 2009, Van Landeghem et al27 presented the first 
postmortem neuropathological study of three patients with 
glioblastoma undergoing MHT (Table 5). In this study, the 
eligibility criteria were: greater than or equal to 18 years, life 
expectancy greater than 3 months, tumor diameter less than 
5 cm, no multilocular growth, and no metal material near the 
tumor focus. After recurrence of the tumor, MHT was applied 
as a second line of treatment and was always associated with 
other therapies (see Table 5). The quantity of magnetic liquid 
instilled into the tumor varied from 4.2 to 4.5 mL. With the 
application of AMF, the temperature achieved among the 
patients ranged between 49.5°C and 65.6°C.
After application of the MHT, survival ranged from 2.1 
to 7.9 months (for details see Table 5). The anatomopatho-
logical results and other findings listed in Table 5 describe 
the presence of many nanoparticles in the tumor region, 
  macrophages in the main extension, and a subsequent necrotic 
area inherent in the tumor. A histological analysis showed that 
the nanoparticles injected were dispersed or in the form of 
clusters, and that the necrotic regions were confined to the local 
instillation of nanoparticles, indicating the need for instillation 
in multiple locations. Immunohistochemical data revealed that 
the internalization of the nanoparticles was mainly driven by 
macrophages and minimally by tumor cells. It was suggested 
that the internalization by macrophages would be promoted by 
applying MHT and yet it promoted necrosis with subsequent 
infiltration and activation of phagocytes.
Later, Maier-Hauff et al7 presented a study of 66 patients 
using the MHT associated with radiotherapy. In this study, they 
investigated whether MHT was able to increase survival of 
patients with recurrent glioblastoma multiforme. The criteria 
for eligibility were:   histological diagnosis of supratentorial 
glioblastoma; evidence of recurrence or progression with 
up to three additional foci; tumor with a maximum of 7 cm; 
absence of tumor infiltration in the ventricle, brain stem, 
  corpus callosum, or the contralateral side; aged between 
18 and 75 years; score $69 in the Karnofsky test; and life 
expectancy of up to 3 months. Seven of 66 patients did not 
attend the inclusion criteria, which resulted in 59 patients 
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In the following year, Shinkai et al34 obtained similar results 
to those obtained from the studies of Yanase in Fisher rats 
that received three sessions of hyperthermia, and they noted 
a significant antitumor immune response against repeated 
inductions of heat. Following this line of study, in 2003, 
Ito et al29 demonstrated that the immune response observed 
in tumors undergoing MHT would be primarily activated by 
HSPs that had increased from the elevation of temperature, 
both in in vitro and in vivo   experiments. A significant increase 
in HSP70 was observed in this study.
From the year 2000, there was an intention of   associating 
hyperthermia with other therapies for the treatment of 
gliomas. Ito et al36 found that the application of a promoter 
of TNF (pGadFNT) associated with the MCL in the tumor 
and the subsequent application of AMF would lead to over-
expression of TNF-α, significantly reducing the tumor tis-
sue. Similarly, Le et al35 found an increased affinity of MCL 
to tumorigenic cells with the association of an antibody 
fragment (Fab), leading to a reduction in tumor growth. 
These data suggested that hyperthermia associated with other 
therapies could potentiate its effect.
In 2002, studies that sought new nanocomposites with differ-
ent coatings, which were able to destroy glioma cells by generat-
ing heat, were initiated. In this sense, Ohno et al37 evaluated the 
efficacy of stick-type CMC. It was noted, after three sessions of 
AMF, that there was a good   distribution of these nanoparticles 
in the tumor tissue, with no detection in the tissues surrounding 
the tumor. The efficient heating through these nanoparticles led 
to remission of the tumors. By then, Jordan et al23 had tested 
two new coats:   carboxidextran and aminosilane. Aminosilane 
was more effective compared with carboxidextran, showing a 
decrease in cell proliferation in the region of the tumor and an 
increase in the survival of animals that used this nanoparticle. 
Yet, in the evaluation of new nanocomposites, Meenach et al30 
  verified in in vitro tests, the ability of nanoparticles immersed 
in hydrogel (PEG) to promote hyperthermia. The application of 
hydrogel lysed glioblastoma cells into the culture did not affect 
the cells that were around the gel, showing their effectiveness 
in reaching only cells bathed by the gel.
Recently, Rabias et al39 characterized a new nanoparticle 
with a high surface charge (maghemite coated with dextran) 
with excellent heating in both in vitro and in vivo tests. In this 
study, the model of glioblastoma was performed in Wistar 
rats (model C6). The heating was achieved satisfactorily with 
the instillation of small volumes of   ferrofluid, and presented 
a good distribution in tumor. The nanoparticle was able, in 
some cases, to promote complete dissolution of the tumor 
tissue. Its efficiency was attributed to higher surface charge 
and the need for small volumes to get a good warming-up.
being included in the survival   statistical analysis. The average 
of ferrofluid injected was 4.5 mL, corresponding to an average 
of 0.28 mL of ferrofluid per cm3 of tumor volume. The AMF 
(100 kHz) applied ranged from 2 to 15 kA/m. Radiotherapy 
was applied before or after thermotherapy, with an average 
dose of 30 Gy, using fractions of 5 × 2 Gy weekly.
In general, two aspects were studied: patient survival 
after the diagnosis of first recurrence of the tumor (OS-2) 
and survival after the diagnosis of primary tumor (OS-1). 
In the OS-2 group, the average survival of 13.4 months 
was higher compared with 6.2 months in conventional 
  treatments realized by Stupp et al.40 The OS-1 group average 
was 23.2 months in contrast with the study by Stupp, where 
the average was 14.6 months. In this study, the increase in 
survival of patients could be correlated to thermotherapy in 
association with radiotherapy. In addition, thermotherapy 
showed few side effects and no serious complication, being 
a good treatment option when compared with conventional 
therapies.
Discussion
The studies selected for this review sought to evaluate the 
use of the technique of MHT to treat gliomas with assays in 
cell culture, animal models, and clinical trials. Some of these 
studies showed possible mechanisms triggered by hyper-
thermia leading to death of the tumor cells, in addition to 
associating hyperthermia with other therapeutic modalities.
The studies that were aimed at the use of MHT in glioma 
cells (T-9) began with Shinkai,28 through the development 
of nanoparticles coated with cationic liposomes (MCL), as 
they were efficient in generating heat, besides having a high 
affinity to the cell surface, as they are positively charged. The 
efficiency of MCL was confirmed by Yanase31 with glioma 
T-9 cells, preincubated with MCL which were destroyed 
after subcutaneous implantation in Fisher rats and subsequent 
application of AMF. Yanase et al32 also observed that MCL 
had good distribution after application of AMF, and the best 
therapeutic strategy in Fisher rats that had developed tumors 
was the application of three sessions of magnetic radiation. 
With these studies, it was concluded that MCL could be a 
nanoparticle functionalized with a good performance for 
application in MHT.
After confirming the efficiency of MCL, these authors 
sought to investigate the mechanisms of destruction of glioma 
tumor cells that could be triggered by MHT. Yanase et al33 
proposed that MHT would be responsible for an antitumor 
immune response. In this study, they found that hyperthermia 
induced and promoted an increase of immune cells CD3, CD4, 
and CD8, and NK cells, in the tumor tissue of Fisher rats. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The development of new nanocomposites made the 
hyperthermia process effective in achieving the desired 
temperature in a localized manner, which brought great 
benefits to patients who used this treatment.
Clinical studies of MHT began with Jordan et al41 who 
presented a new system of application of the magnetic 
field to generate hyperthermia, using magnetic fluids, for 
future applications in the treatment of glioblastomas and 
prostate carcinoma. However, in 2007, Maier-Hauff et al6 
presented a clinical study of 14 patients where MHT was 
applied (  combined with radiotherapy) for the treatment 
of   glioblastomas. A good tolerability to the technique was 
observed by the patients, without any major side effects. 
Four patients in this study died, although their deaths were 
not related to tumor progression or thermotherapy. This 
could be an indication that the technique of MHT would 
stop the development of the tumor, thus promising the use 
of thermotherapy in tumor control, but it is still necessary 
to have many more studies. In 2009, Van Landeghem et al27 
performed a postmortem study in patients with glioblastoma 
undergoing MHT. The anatomopathological examination 
verified the presence of many nanoparticles that were 
dispersed or in an aggregated form, in the tumor tissues. The 
necrotic regions were limited to areas of instillation of the 
nanoparticles, which showed that application to more areas 
was necessary to reach all tumor tissues. It was also found 
that internalization of the nanoparticles was mainly driven 
by macrophages and not by tumor cells.
In 2010, following the clinical studies, Maier-Hauff et al7 
performed a study of 69 patients with recurrent glioblastoma 
who underwent radiotherapy in combination hyperthermia 
induced by magnetic nanoparticles. The results of this paper 
displayed differently to their initial studies, an increase in patient 
survival when compared with conventional therapies.40
Another advantage was the low doses of radiation applied, 
suggesting that thermotherapy had a major role in increasing 
survival to these patients. Moreover, it was proposed that this 
new therapy can be applied in other tumor tissues of the body, 
since they have similar sensitivity to warming.
Conclusion
In this review we have discussed the application of magnetic 
hyperthermia for the treatment of gliomas. MHT had its 
efficacy demonstrated through experiments in vitro where the 
application of MHT to tumor cell culture promoted cell death 
by necrosis and/or apoptosis, or even via thermal ablation. 
This effectiveness was confirmed in the experimental models 
of rodents where an increase in survival and, in some cases, 
a decrease or total regression of tumor mass was observed. 
In addition, in the first clinical trials, MHT was seen to be 
promising when combined with other conventional therapies, 
as a complementary therapy.
Based on these data, we can conclude that MHT has shown 
to be effective in many cases; however, an improvement of 
nanocomposites as well as the upgrading of equipment for 
induction of AMF, could contribute to the establishment of 
technique in the treatment of gliomas.
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